<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442689</url>
  </required_header>
  <id_info>
    <org_study_id>DK73411</org_study_id>
    <secondary_id>R01DK073411</secondary_id>
    <nct_id>NCT00442689</nct_id>
  </id_info>
  <brief_title>Metabolic Syndrome in PCOS: Precursors and Interventions</brief_title>
  <official_title>Metabolic Syndrome in PCOS: Precursors and Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the metabolic effects of anti-androgens and oral
      contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We
      hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs
      would produce improvement in metabolic markers in PCOS women and would reduce their long term
      metabolic risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is one of the most common conditions of young women, and it
      is frequently associated with insulin resistance or metabolic syndrome (MBS). In addition,
      affected women have significantly elevated mean low-density lipoprotein (LDL) levels and an
      increased prevalence of at risk LDL levels, independent of obesity. We are directly testing
      the role of androgens in the metabolic abnormalities in PCOS by examining the impact of
      direct androgen receptor blockade by anti-androgen medications and indirect suppression of
      androgen production through suppression of leutinizing hormone (LH) with oral contraceptive
      pills (OCPs), compared with placebo, on visceral adiposity, circulating LDL levels, insulin
      secretion and sensitivity as measured by frequently-sampled IV glucose tolerance tests
      (FSIGT) and oral glucose tolerance tests (OGTT), resting energy expenditure, and maximal
      aerobic capacity measurement.

      Note: Originally there were 2 additional study arm, Metformin only and Metformin + Flutamide.
      These study arms were ultimately eliminated and were not included in analysis of baseline
      characteristics or endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Low-density Lipoprotein (LDL) Levels Over the Study Period</measure>
    <time_frame>6 months</time_frame>
    <description>Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in High-density Lipoprotein (HDL) Levels During Study Period</measure>
    <time_frame>6 months</time_frame>
    <description>Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI</measure>
    <time_frame>6 months</time_frame>
    <description>Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period</measure>
    <time_frame>6 months</time_frame>
    <description>Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Disposition Index</measure>
    <time_frame>6 months</time_frame>
    <description>Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Resting Energy Expenditure (REE) Over the Study Period</measure>
    <time_frame>6 months</time_frame>
    <description>Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period</measure>
    <time_frame>6 months</time_frame>
    <description>Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral contraceptive (35 mg ethinyl estradiol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flutamide 250 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
    <description>250 mg twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Eulexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol 35 mcg and drospirenone 3 mg</intervention_name>
    <description>one active pill per day for three weeks and then 1 sugar pill per day for one week</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Yasmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>3</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 periods or fewer per year

          -  Overweight

          -  All ethnicities

        Exclusion Criteria:

          -  Diabetes

          -  Heart Disease

          -  Chronic illness

          -  Regular Smokers

          -  Current use of Birth Control Pills, Patch, Ring, Depo
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Dunaif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998 Aug;83(8):2699-705.</citation>
    <PMID>9709934</PMID>
  </reference>
  <reference>
    <citation>Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006 Oct;91(10):3970-80. Epub 2006 Jul 25.</citation>
    <PMID>16868063</PMID>
  </reference>
  <reference>
    <citation>Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004 Feb;60(2):241-9.</citation>
    <PMID>14725687</PMID>
  </reference>
  <reference>
    <citation>Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab. 2007 Nov;92(11):4191-8. Epub 2007 Sep 4.</citation>
    <PMID>17785364</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <results_first_submitted>April 9, 2014</results_first_submitted>
  <results_first_submitted_qc>May 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2014</results_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Andrea Dunaif</investigator_full_name>
    <investigator_title>Charles F Kettering Professor of Endocrinology &amp; Metabolism Vice Chair for Research, Department of Medicine Northwestern University, Feinberg School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>PCOS</keyword>
  <keyword>overweight</keyword>
  <keyword>infertility</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>menstrual cycle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>97 total subjects enrolled. Prior to randomization, 16 subjects were excluded or dropped out, leaving 81 active subjects. Early in the study, 2 of the 5 study arms were discontinued: participants receiving Metformin only (8 subjects) and those receiving Metformin + Flutamide (6 subjects) - leaving 67 subjects whose data were analyzed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Contraceptive - 1</title>
          <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)
Oral contraceptive: one active pill per day for three weeks and then 1 sugar pill per day for one week</description>
        </group>
        <group group_id="P2">
          <title>Flutamide - 2</title>
          <description>Flutamide
Flutamide: 250 mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo - 3</title>
          <description>Placebo only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Contraceptive - 1</title>
          <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
        </group>
        <group group_id="B2">
          <title>Flutamide - 2</title>
          <description>Flutamide
Flutamide: 250 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo - 3</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="4"/>
                    <measurement group_id="B2" value="28" spread="4"/>
                    <measurement group_id="B3" value="28" spread="5"/>
                    <measurement group_id="B4" value="28" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="5.5"/>
                    <measurement group_id="B2" value="40.1" spread="5.6"/>
                    <measurement group_id="B3" value="40.0" spread="6.7"/>
                    <measurement group_id="B4" value="39.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Low-density Lipoprotein (LDL) Levels Over the Study Period</title>
        <description>Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low-density Lipoprotein (LDL) Levels Over the Study Period</title>
          <description>Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" spread="17"/>
                    <measurement group_id="O2" value="-9" spread="14"/>
                    <measurement group_id="O3" value="-7" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in High-density Lipoprotein (HDL) Levels During Study Period</title>
        <description>Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-density Lipoprotein (HDL) Levels During Study Period</title>
          <description>Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="4"/>
                    <measurement group_id="O2" value="-5" spread="7"/>
                    <measurement group_id="O3" value="-2" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI</title>
        <description>Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI</title>
          <description>Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT)</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.6"/>
                    <measurement group_id="O3" value="0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period</title>
        <description>Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period</title>
          <description>Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage)</description>
          <units>percentage of body mass</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.5"/>
                    <measurement group_id="O2" value="-1.9" spread="3.9"/>
                    <measurement group_id="O3" value="-1.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Disposition Index</title>
        <description>Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disposition Index</title>
          <description>Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI)</description>
          <units>min^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1653" spread="6008"/>
                    <measurement group_id="O2" value="194" spread="1424"/>
                    <measurement group_id="O3" value="-184" spread="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Resting Energy Expenditure (REE) Over the Study Period</title>
        <description>Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Resting Energy Expenditure (REE) Over the Study Period</title>
          <description>Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE)</description>
          <units>Kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="209"/>
                    <measurement group_id="O2" value="-79" spread="239"/>
                    <measurement group_id="O3" value="-88" spread="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period</title>
        <description>Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Contraceptive - 1</title>
            <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)</description>
          </group>
          <group group_id="O2">
            <title>Flutamide - 2</title>
            <description>Flutamide
Flutamide: 250 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo - 3</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period</title>
          <description>Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max)</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="6.5"/>
                    <measurement group_id="O2" value="-1.6" spread="4.4"/>
                    <measurement group_id="O3" value="1.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months - adverse event data collected over the study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Contraceptive - 1</title>
          <description>Oral contraceptive (containing 35mcg of ethinyl estradiol and 3mg of drospirenone)
Oral contraceptive: one active pill per day for three weeks and then 1 sugar pill per day for one week</description>
        </group>
        <group group_id="E2">
          <title>Flutamide - 2</title>
          <description>Flutamide
Flutamide: 250 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo - 3</title>
          <description>Placebo only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal LFTs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Please note there were 2 additional arms at the start of the study: Metformin alone (n=8) and Metformin+Flutamide (n=6), which were discontinued. These arms are therefore not included in these results data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Laura Torchen</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-227-6492</phone>
      <email>ltorchen@luriechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

